Event dossier

Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion

Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.

1 report1 sourceApr 20, 2026, 2:41 PM
FilterCNBC
Clustered coverageCNBC
Coverage timeline1
Coverage timeline

Coverage timeline

Ranked reports inside the event cluster. Open any publisher link to read the original coverage.

CNBCApr 20, 2026, 2:41 PM

Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion

Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.

Related events

Related events

Nearby clusters pulled from title, summary, and keyword similarity in PostgreSQL.